Leap Therapeutics Q2 net loss $13.4M; DKN-01 CRC trial advances to Part B

CYPHERPUNK TECHNOLOGIES INC.

2023-Q2 EPS reported -$4.01

Net loss $13.4M in Q2 2023 vs $17.0M in Q2 2022; R&D expenses fell to $11.1M.
Cash and equivalents $91.4M at June 30, 2023; interest income $1.2M.
DeFianCe Part A CRC study achieved >20% ORR; 130-patient randomized Part B initiated.
DisTinGuish GEA data: 73% ORR (mITT), median OS 19.5 months, median PFS 11.3 months.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CYPHERPUNK TECHNOLOGIES INC. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 14, 2023, Leap Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

CYPHERPUNK TECHNOLOGIES INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-090875

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.